Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation

Lisa P. Abramson, Elfriede Pahl, Lijun Huang, Veronica Stellmach, Sherrie Rodgers, Constantine Mavroudis, Carl L. Backer, Robert M. Arensman, Susan E. Crawford

Research output: Contribution to journalArticle

Abstract

Background. Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. Methods. Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. Results. Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the nonrejecting transplant group (700.7±154 pg/ml vs. 190.5±29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. Conclusions. These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.

Original languageEnglish (US)
Pages (from-to)153-156
Number of pages4
JournalTransplantation
Volume73
Issue number1
DOIs
StatePublished - Jan 15 2002
Externally publishedYes

Fingerprint

Heart Transplantation
Vascular Endothelial Growth Factor A
Pediatrics
Serum
Allografts
Transplants
Biopsy
Immunosuppressive Agents
Enzyme-Linked Immunosorbent Assay
Survival
Therapeutics
Population

ASJC Scopus subject areas

  • Transplantation

Cite this

Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. / Abramson, Lisa P.; Pahl, Elfriede; Huang, Lijun; Stellmach, Veronica; Rodgers, Sherrie; Mavroudis, Constantine; Backer, Carl L.; Arensman, Robert M.; Crawford, Susan E.

In: Transplantation, Vol. 73, No. 1, 15.01.2002, p. 153-156.

Research output: Contribution to journalArticle

Abramson, LP, Pahl, E, Huang, L, Stellmach, V, Rodgers, S, Mavroudis, C, Backer, CL, Arensman, RM & Crawford, SE 2002, 'Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation', Transplantation, vol. 73, no. 1, pp. 153-156. https://doi.org/10.1097/00007890-200201150-00030
Abramson, Lisa P. ; Pahl, Elfriede ; Huang, Lijun ; Stellmach, Veronica ; Rodgers, Sherrie ; Mavroudis, Constantine ; Backer, Carl L. ; Arensman, Robert M. ; Crawford, Susan E. / Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. In: Transplantation. 2002 ; Vol. 73, No. 1. pp. 153-156.
@article{f884499858bf4fcfa9e073db1aa7722d,
title = "Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation",
abstract = "Background. Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. Methods. Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. Results. Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the nonrejecting transplant group (700.7±154 pg/ml vs. 190.5±29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. Conclusions. These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.",
author = "Abramson, {Lisa P.} and Elfriede Pahl and Lijun Huang and Veronica Stellmach and Sherrie Rodgers and Constantine Mavroudis and Backer, {Carl L.} and Arensman, {Robert M.} and Crawford, {Susan E.}",
year = "2002",
month = "1",
day = "15",
doi = "10.1097/00007890-200201150-00030",
language = "English (US)",
volume = "73",
pages = "153--156",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation

AU - Abramson, Lisa P.

AU - Pahl, Elfriede

AU - Huang, Lijun

AU - Stellmach, Veronica

AU - Rodgers, Sherrie

AU - Mavroudis, Constantine

AU - Backer, Carl L.

AU - Arensman, Robert M.

AU - Crawford, Susan E.

PY - 2002/1/15

Y1 - 2002/1/15

N2 - Background. Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. Methods. Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. Results. Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the nonrejecting transplant group (700.7±154 pg/ml vs. 190.5±29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. Conclusions. These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.

AB - Background. Early detection and treatment of acute rejection in cardiac transplant recipients significantly improves long-term survival. Endomyocardial biopsy is used routinely for diagnosing allograft rejection; however, in young children, this procedure carries some risk. We evaluated serum vascular endothelial growth factor (VEGF) as a potential surveillance marker of acute cellular rejection. Methods. Blood samples (n=62) were analyzed from 23 patients and compared with controls (n=18) using an ELISA for VEGF. Results were correlated with endomyocardial biopsy rejection grades. Results. Mean baseline VEGF levels of the transplant population were consistently higher than controls. Serum VEGF levels were significantly higher during acute cellular rejection when compared with the nonrejecting transplant group (700.7±154 pg/ml vs. 190.5±29 pg/ml). VEGF decreased two- to eightfold after immunosuppressive therapy in 9 of 11 rejection episodes. Conclusions. These data suggest that VEGF may play a role in the pathogenesis of acute allograft rejection and it may serve as a reliable serologic surveillance marker.

UR - http://www.scopus.com/inward/record.url?scp=0037080618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037080618&partnerID=8YFLogxK

U2 - 10.1097/00007890-200201150-00030

DO - 10.1097/00007890-200201150-00030

M3 - Article

C2 - 11792998

AN - SCOPUS:0037080618

VL - 73

SP - 153

EP - 156

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -